reason report
bottom line report earn fiscal quarter
releas top-lin data first patient treat
program view releas larg line
earli present healthi volunt though modest ldl-c
knockdown rais question competit
hypercholesterolemia compar inclisiran lower unadjust
peak sale hypercholesterolemia
bring pt reiter under-perform rate
financi glanc revenu quarter
attribut revenu recognit up-front payment
mileston collabor janssen op
manag expect remain revenu
partnership fulli recogn calendar year spend
estim sg spend
higher project quarter
call manag guid cash burn
per quarter decemb held cash cash
equival invest
first-in-pati data program
consist healthi volunt data releas interim
data three patient sever hypertriglyceridemia least day
first dose mg patient demonstr mean maximum
triglycerid tg reduct mean maximum
reduct top-lin interim data hypercholesterolemia
patient stabl statin regimen without ezetimib
receiv inhibitor least day data
lipoprotein cholesterol reduct mean maximum
reduct hypertriglyceridemia patient
least day data demonstr mean maximum tg reduct
mean maximum reduct safeti
profil drug report consist drug
arwr pipelin drug-rel discontinu
common advers event headach respiratori tract infect
though cross-trial comparison inclisiran rais concern
clinic relev hypercholesterolemia
view data appear inferior inclisiran even multipl
factor stack deck favor first reduct ldl-c
numer lower inclisiran ldl-c reduct
year price history/av daili volume mil
compani inform svb leerink llc research
revenu million
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
compar
inclisiran secondli arwr data present
mean maxim reduct day compar time-averag
valu day skew data sharpli favor
addit orion phase trial result placebo-adjust enrol
thousand patient day follow-up top-lin data
releas dataset placebo-adjust
despit present data three patient day follow-
demonstr lower ldl-c reduct inclisiran
recept argument patient treat could
lower reduct ldl-c manag commentari disclosur
last night suggest minor patient given depth
knockdown opportun increas knockdown
increas benefit slim unclear find
clinic util without lengthi expens cardiovascular outcom
trial cvot believ like come short vs
inclisiran cross-trial basi inclisiran year lead time
expect launch low price global
back larg nv sale forc question wisdom
continu pursu target hypercholesterolemia
set
potenti aro-hsd transact sourc upsid risk
prepar remark manag comment
gener unsolicit inbound interest larg pharma
believ one sought asset nash
moment program still earli stage compani plan
dose first patient phase studi late quarter earli next
quarter recogn partnership involv asset larg
up-front payment could lead upsid risk account
model chang increment increas sg spend
match compani guidanc cash burn
quarter respons concern competit aro-
hypercholesterolemia lower out-year market penetr
chang lower pt
rate share under-perform lead asset aro-aat ahead
oligotherapeut compani competitor pathway approv dataset
on-going sequoia studi remain uncertain small molecul corrector data
potenti existenti threat program partner hbv program sourc
non-dilut financ potenti royalti cash flow fulli valu current
level remain asset arwr pipelin consist cardiovascular lipid franchis
made asset earli human trial number unproven non-liv program
remain exceedingli earli target genet valid face well-fund
competit anti-sens oligonucleotid partner establish pharma player
suggest orphan price necessari captur valu asset
may realiz launch drug lower-pr competitor broad
label robust dataset sizeabl sale forc outsid arwr core compet current
valuat share bake substanti technolog valu base assumpt
trim platform safe effect extrapol dataset present rnai pioneer
may prove incorrect given patient-year exposur
trim platform date
price target base discount cash flow methodolog
project potenti sale royalti aro-aat
risk-adjust basi explicitli model expens forecast result cash
flow assign termin growth rate discount rate consist
clinical-stag pre-revenu compani coverag univers addit
includ arwr net cash balanc valuat
major risk view outlook valuat share activ includ
acquisit compani substanti premium stand-alon valu addit risk
includ major chang reimburs coverag rare diseas agent unexpect
safeti signal clinic develop candid trim platform forecast
subject unmodel competitor entrant includ gene edit disrupt technolog
could potenti compet share rnai-bas therapi develop compani
partner convers forecast may prove conserv competit agent
compet rnai agent vrtx oral candid defici fail
progress clinic trial unprofit like remain time greater-
than-expect oper expens cash burn could lead dilut equiti issuanc
frequent less attract valuat project convers greater-than-expect non-
dilut partnership capit inflow oper expens project would present
upsid risk view
research develop
gener administr expens
sale market
chang valu deriv
total incom expens
loss incom tax
provis incom tax
research develop
 ex sale market
sale market revenu
sec file svb leerink research estim
cash equival
properti equip net
accru payrol benefit
defer revenu net current portion
note payabl net current portion
accumul comprehens incom loss
total liabil stockhold equiti
sec file svb leerink research estim
chang valu deriv
depreci amort
amort accret note premium discount
prepaid expens current asset exclud receiv
princip payment capit leas note payabl
payment tax net share settl restrict stock unit
proce exercis warrant stock option
proce issuanc common stock prefer stock net
net increas decreas cash
begin period
end period
net cash use oper activ
purchas properti equip
purchas market secur
proce sale market secur
net cash use provid invest activ
net cash provid use financ activ
